Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years
Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years
$Ocugen(OCGN.US)$ announced the publication of positive pediatric Phase 2/3 study results in children aged 2–18 years for COVID-19 vaccine, Covaxin (BBV152), in The Lancet Infectious Diseases.
Covaxin is developed and manufactured by Ocugen's India-based partner Bharat Biotech International Limited.
It is under clinical investigation by Ocugen in the U.S. for use in adults aged 18 years and older.
Related: FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial.
The low reactogenicity can potentially make Covaxin more acceptable in pediatric populations than the more reactogenic mRNA vaccines.
Bharat Biotech's pediatric Phase 2/3 study showed no serious adverse events, deaths, or withdrawals due to an adverse event, including no cases of Guillain-Barré syndrome, thromboembolic events, myocarditis, pericarditis, or other adverse events of particular interest being observed to date.
Data comes from 526 children. Local reactions mainly consisted of mild injection site pain.
Geometric mean titers of microneutralization antibodies at day 56 were similar to titers in vaccinated adults.
Price Action: OCGN shares are up 4.63% at $2.26 during the market session on the last check Tuesday.
$Ocugen(OCGN.US)$ announced the publication of positive pediatric Phase 2/3 study results in children aged 2–18 years for COVID-19 vaccine, Covaxin (BBV152), in The Lancet Infectious Diseases.
Covaxin is developed and manufactured by Ocugen's India-based partner Bharat Biotech International Limited.
It is under clinical investigation by Ocugen in the U.S. for use in adults aged 18 years and older.
Related: FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial.
The low reactogenicity can potentially make Covaxin more acceptable in pediatric populations than the more reactogenic mRNA vaccines.
Bharat Biotech's pediatric Phase 2/3 study showed no serious adverse events, deaths, or withdrawals due to an adverse event, including no cases of Guillain-Barré syndrome, thromboembolic events, myocarditis, pericarditis, or other adverse events of particular interest being observed to date.
Data comes from 526 children. Local reactions mainly consisted of mild injection site pain.
Geometric mean titers of microneutralization antibodies at day 56 were similar to titers in vaccinated adults.
Price Action: OCGN shares are up 4.63% at $2.26 during the market session on the last check Tuesday.
$Ocugen(OCGN.US)$ 宣佈在《柳葉刀傳染病》雜誌上發表新冠肺炎疫苗Covaxin(BBV152)在2-18歲兒童中的兒科2/3期陽性研究結果。
Covaxin是由Ocugen的印度合作伙伴Bharat Biotech International Limited開發和製造的。
它正在由美國Ocugen公司進行臨牀研究，用於18歲及以上的成年人。
相關： FDA取消Ocugen的COVID疫苗試驗的臨牀擱置.
與更具反應性的mRNA疫苗相比，低反應性可能會使Covaxin更容易被兒科人羣接受。
Bharat Biotech的兒科2/3期研究顯示，到目前為止，沒有觀察到嚴重的不良事件、死亡或因不良事件導致的停藥，包括格林-巴利綜合徵、血栓栓子事件、心肌炎、心包炎或其他特別感興趣的不良事件。
數據來自526名兒童。局部反應主要表現為注射部位輕度疼痛。
在第56天，微量中和抗體的幾何平均滴度與接種疫苗的成人相似。
價格行動：週二尾盤，OCGN股價上漲4.63%，至2.26美元。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧